SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Evogene Ltd.

(Name of Issuer)

Ordinary shares, par value NIS 0.20 per share

(Title of Class of Securities)

M4119S187

(CUSIP Number)

Nitsan Deutsch
13 Gad Feinstein Street, Park Rehovot, c/o Evogene Ltd.
Rehovot, IL, 7638517
972-8-9311900

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/11/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP Number(s):

M4119S187

Name of reporting person

RECANATI LEON

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

ISRAEL

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,354,836.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,354,836.00
10	Shared Dispositive Power 0.00

Aggregate amount beneficially owned by each reporting person

1,354,836.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

8.6 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person:

(1) The percentage of Ordinary Shares beneficially owned by the Reporting Person is based on 15,801,407 Ordinary Shares outstanding as of July 27, 2026, as reported by the Issuer in the Issuer's Proxy Statement for its 2026 Annual General Meeting of Shareholders, dated July 31, 2026, attached as Exhibit 99.2 to the Issuer's Form 6-K that was furnished to the U.S. Securities and Exchange Commission on July 31, 2026. The aggregate beneficial ownership includes 10,950 Ordinary Shares underlying share options held by the Reporting Person that are currently exercisable or exercisable within 60 days of August 11, 2026.

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Ordinary shares, par value NIS 0.20 per share

(b)

Name of Issuer:

Evogene Ltd.

(c)

Address of Issuer's Principal Executive Offices:

13 Gad Feinstein Street, Park Rehovot, Rehovot, ILLINOIS , 7638517.

Item 2.

Identity and Background

(a)

Leon Recanati (the "Reporting Person").

(b)

27 Yoav St., Tel Aviv 6908165, Israel.

(c)

Mr. Recanati serves as a member of the board of directors of Evogene Ltd. (the "Issuer"). Mr. Recanati is also the founder and principal of GlenRock Israel, a family office investment company that manages the investment activities of the Recanati family and invests primarily in companies engaged in technology, life sciences, cyber, and agritech. The address of Mr. Recanati's principal office and principal place of business is 85 Medinat Hayehudim Street, Tower G, 8th Floor, Herzliya Business Park, Herzliya 4676670, Israel.

(d)

During the last five years, Mr. Recanati has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)

During the last five years, Mr. Recanati has not been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.

(f)

Mr. Recanati is a citizen of the State of Israel.

Item 3.

Source and Amount of Funds or Other Consideration

Item 3 of the original Statement of Beneficial Ownership on Schedule 13D filed by the Reporting Person on August 11, 2026 (the "Original Statement") is hereby amended and supplemented by adding the following: On August 11, 2026, the Reporting Person purchased an additional 460,000 Ordinary Shares in open market transactions at a purchase price of $0.635 per share, for aggregate consideration of $292,100. The source of funds used to acquire those additional Ordinary Shares was the personal funds of the Reporting Person.

Item 4.

Purpose of Transaction

Item 4 of the Original Statement is incorporated by reference herein and is furthermore hereby amended and supplemented by adding the following: On August 11, 2026, the Reporting Person purchased 460,000 Ordinary Shares. Except as set forth herein or in the Original Statement, the Reporting Person does not currently have any plans or proposals that relate to or would result in any of the transactions or other matters specified in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Item 5.

Interest in Securities of the Issuer

(a)

As of the date of this Amendment No. 1 to the Original Statement, the Reporting Person beneficially owns an aggregate of 1,354,836 Ordinary Shares, representing approximately 8.6% of the outstanding Ordinary Shares of the Issuer, consisting of (i) 1,343,886 Ordinary Shares held directly, and (ii) 10,950 Ordinary Shares underlying share options that are currently exercisable or exercisable within 60 days of August 11, 2026. The percentage of Ordinary Shares beneficially owned by the Reporting Person is based on 15,801,407 Ordinary Shares outstanding as of July 27, 2026, as reported by the Issuer in the Issuer's Proxy Statement for its 2026 Annual General Meeting of Shareholders, dated July 31, 2026, attached as Exhibit 99.2 to the Issuer's Report of Foreign Private Issuer on Form 6-K that was furnished to the SEC on July 31, 2026.

(b)

The Reporting Person has sole voting power and sole dispositive power with respect to all 1,354,836 Ordinary Shares beneficially owned by him, which are held directly by him (including 10,950 Ordinary Shares underlying share options that are currently exercisable or exercisable within 60 days of August 11, 2026). No other person has shared voting or dispositive power with respect to such shares.

(c)

On August 11, 2026, the Reporting Person purchased an additional 460,000 Ordinary Shares of the Issuer in open market transactions at a price of $0.635 per share. Prior to this purchase, the Reporting Person had held 883,886 Ordinary Shares directly (besides shares underlying exercisable options).

(d)

Not applicable.

(e)

Not applicable.

Item 6.

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

There are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities of the Issuer, including but not limited to the transfer or voting of any such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

RECANATI LEON

Signature:	/s/ Leon Recanati
Name/Title:	Leon Recanati
Date:	08/13/2026